



Wanbury Limited

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

September 12, 2024

To The Manager, Listing Departments, BSE Limited, P. J. Towers, Da1a1 Street, Mumbai - 400 001. Scrip Code: 524212	To, The Manager, Listing Department, National Stock Exchange of India Limited, Exchange Plaza, C - 1, Block- G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Symbol: WANBURY
--	--

Dear Madam/ Sir,

Sub.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Wanbury's API Product Portfolio and Pipeline

Wanbury Limited would like to inform you about its new products launch, its commercialization and pipeline as under:

Commercialized API Products					
API	Therapeutic Area	Pharmacopeial Details	USDMF	CEP	Global Demand (MT)
Metformin HCl	Anti-Diabetic	USP, Ph.Eur, BP, and IP	Y	Y	61,400
Sertraline HCl	Anti - depressant	USP, Ph.Eur, BP and IP	Y	Y	650
Diphenhydramine HCl	Anti-histamine	USP, Ph.Eur, BP and IP	Y	Y	291
Diphenhydramine Citrate	Anti-histamine	USP	Y	NA	
Tramadol HCl	Analgesic	USP, Ph.Eur, BP and IP	Y	Y	556
Paroxetine HCl	Anti - depressant	USP, Ph.Eur and BP	Y	Y	68
Mefenamic Acid	Anti - Inflammatory	USP, Ph.Eur and BP	Y	Y	1,469
New APIs to be launched in FY24-25					
API	Therapeutic Area	Pharmacopeial Details	USDMF	CEP	Global Demand (MT)
Dextromethorphan HBr	Antitussives	USP, Ph.Eur, and IP	Y	Y	209
Ketamine HCl	Anaesthetic	USP, Ph.Eur and IP	Y	Under Filing	4

Note: Global demand data includes only prescription sales for FY24; Source: Cortellis.

**Wanbury Limited**

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

API Product Pipeline			
API	Therapeutic Area	Current Status	Global Demand (MT)
Rivaroxaban	Anti-Coagulant	Tech pack available	65
Quetiapine Fumarate	Atypical antipsychotics	USDMF Filed	675
Montelukast Sodium	Antileukotriene Anti-Asthmatics	Plant Validation by Dec'24	82
Imeglimin HCl	Anti-Diabetic	Plant Validation by Q1'25	101
Sitagliptin Phosphate Monohydrate	Anti-Diabetic	Plant validation by Dec'24	609

Note: Global demand data includes only prescription sales for FY24; Source: Cortellis

Thanking you,

Yours truly,
For Wanbury Limited

Jitendra J. Gandhi
Company Secretary